Organisms require an appropriate balance of stability and reversibility in gene expression
programmes to maintain cell identity or to enable responses to stimuli; epigenetic regulation …

EZH2 is the catalytic subunit of Polycomb repressive complex 2 (PRC2), which is a highly
conserved histone methyltransferase that targets lysine-27 of histone H3. This methylated …

Two recurrent mutations, K27M and G34R/V, within histone variant H3. 3 were recently
identified in∼ 50% of pHGGs. Both mutations define clinically and biologically distinct …

Glioblastoma multiforme (GBM) displays cellular hierarchies harboring a subpopulation of
stem-like cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), the lysine methyltransferase …

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States,
which is, in part, due to intrinsic (de novo) and extrinsic (acquired) resistance to conventional …

The commonly mutated genes in pancreatic neuroendocrine tumors (PanNETs) are ATRX,
DAXX, and MEN1. We genotyped 64 PanNETs and found 58% carry ATRX, DAXX, and …

Cancer cells exhibit alterations in histone modification patterns at individual genes and
globally at the level of single nuclei in individual cells. We demonstrated previously that …

G9a is a mammalian histone methyltransferase that contributes to the epigenetic silencing of
tumor suppressor genes. Emerging evidence suggests that G9a is required to maintain the …

The genetic changes leading to the development of human cancer are accompanied by
alterations in the structure and modification status of chromatin, which represent powerful …

Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a
devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to …